A groundbreaking Phase 1 study suggests that once-yearly intramuscular lenacapavir could be a promising option for HIV PrEP.

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

The head of the U.N. AIDS agency says Donald Trump should enable the American company Gilead to roll out its prevention drug ...

By Gift BritonThe once-a-year injectable pre-exposure prophylaxis (PrEP), Lenacapavir, has shown promising results in a recent Phase 1 clinical trial.The trial involved 40 healthy adults aged between ...